FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) FF305 確認 根據《主板上市規則》第13.25C條 / 《GEM上市規則》第17.27C條，我們在此確認，據我們所知所信，第一章節所述的每項股份發行或庫存股份出售或轉讓已獲發行人董事會正式授權批准，並遵 照所有適用上市規則、法律及其他監管規定進行，並在適用的情況下： 表格類別： 股票 狀態： 新提交 公司名稱： 江蘇恒瑞醫藥股份有限公司 呈交日期： 2025年9月29日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | A 股份類別 | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | 600276 ...

智通财经APP讯，恒瑞医药(01276)公布，2025年9月29日耗资约7370.23万元回购108万股A股股份。 ...

恒瑞医药（600276）(01276)公布，2025年9月29日耗资约7370.23万元回购108万股A股股份。 ...

Market Overview - The Shanghai Composite Index rose by 0.90% on September 29, with 26 out of 28 sectors experiencing gains, led by non-bank financials and non-ferrous metals, which increased by 3.84% and 3.78% respectively [1] - The pharmaceutical and biological sector saw a modest increase of 0.17% [1] - The coal and banking sectors were the biggest losers, declining by 0.84% and 0.46% respectively [1] Capital Flow Analysis - The net inflow of capital in the two markets was 9.527 billion yuan, with 13 sectors receiving net inflows [1] - The non-bank financial sector had the highest net inflow of 12.348 billion yuan, corresponding to its 3.84% increase [1] - The non-ferrous metals sector followed with a net inflow of 2.986 billion yuan and a daily increase of 3.78% [1] - Conversely, 18 sectors experienced net outflows, with the electronics sector leading at a net outflow of 2.811 billion yuan, followed by the defense and military sector with 1.882 billion yuan [1] Pharmaceutical and Biological Sector - The pharmaceutical and biological sector had a net outflow of 1.640 billion yuan, with 285 out of 475 stocks in the sector rising, while 169 fell, including 2 hitting the daily limit down [2] - Notable stocks with significant net inflows included Jilin Aodong (10.565 million yuan), Sino Medical (10.067 million yuan), and Mindray Medical (9.186 million yuan) [2] - Major stocks with significant net outflows included Hengrui Medicine (-333.586 million yuan), Guangsheng Tang (-160.353 million yuan), and Hanyu Pharmaceutical (-138.282 million yuan) [4] Top Gainers in Pharmaceutical Sector - Jilin Aodong saw a price increase of 6.69% with a turnover rate of 4.00% and a net inflow of 10.565 million yuan [2] - Sino Medical increased by 4.82% with a turnover rate of 7.00% and a net inflow of 10.067 million yuan [2] - Mindray Medical had a slight increase of 0.19% with a turnover rate of 0.68% and a net inflow of 9.186 million yuan [2] Top Losers in Pharmaceutical Sector - Hengrui Medicine decreased by 1.26% with a turnover rate of 1.02% and a net outflow of 333.586 million yuan [4] - Guangsheng Tang experienced a decline of 6.18% with a turnover rate of 11.07% and a net outflow of 160.353 million yuan [4] - Hanyu Pharmaceutical had a minor increase of 0.24% but still faced a net outflow of 138.282 million yuan [4]

格隆汇9月29日丨恒瑞医药(01276.HK)发布公告，2025年9月29日耗资人民币7370.23万元回购108万股A 股，回购价格每股67.8-69.33元。 ...

Core Insights - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of four injectable drugs, including SHR-7787, SHR-4849, Bevacizumab, and Adebali monoclonal antibody [1][2] Group 1: Drug Approvals - The company’s subsidiaries have been granted clinical trial approval for SHR-7787, a first-class therapeutic biological product that activates T cells to target and kill tumor cells, with no similar drugs currently approved in China [1] - SHR-4849 is an antibody-drug conjugate targeting DLL3, designed to specifically bind to DLL3 antigens on tumor cells, leading to the release of cytotoxic agents to kill cancer cells, aimed at treating advanced malignant solid tumors [1] Group 2: Existing Products - Bevacizumab, a humanized anti-VEGF monoclonal antibody, was co-developed by Genentech and is currently marketed globally, including in China [2] - Adebali monoclonal antibody is a humanized anti-PD-L1 monoclonal antibody developed by the company, which aims to block the PD-1/PD-L1 pathway to reactivate the immune system against tumors [2]

Core Insights - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of four injectable drugs, including SHR-7787, SHR-4849, Bevacizumab, and Adebali monoclonal antibody [1][2] Group 1: Drug Approvals - The company’s subsidiaries have been granted clinical trial approval for SHR-7787, a first-class therapeutic biological product that activates T cells to target and kill tumor cells, with no similar drugs currently approved in China [1] - SHR-4849 is an antibody-drug conjugate targeting DLL3, designed to specifically bind to DLL3 antigens on tumor cells, leading to the release of cytotoxic agents to kill cancer cells, aimed at treating advanced malignant solid tumors [1] Group 2: Existing Products - Bevacizumab, a humanized anti-VEGF monoclonal antibody, was co-developed by Genentech and Roche, approved in the US in 2004, and is currently marketed in China and globally [2] - Adebali monoclonal antibody is a humanized anti-PD-L1 monoclonal antibody developed by the company, which blocks the PD-1/PD-L1 pathway to reactivate the immune system's anti-tumor activity [2]

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-155 江苏恒瑞医药股份有限公司 关于获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）子公司苏州盛迪亚 生物医药有限公司、上海恒瑞医药有限公司、上海盛迪医药有限公司收到国家药 品监督管理局（以下简称"国家药监局"）核准签发关于 SHR-7787 注射液、 SHR-4849 注射液、贝伐珠单抗注射液、阿得贝利单抗注射液的《药物临床试验 批准通知书》，将于近期开展临床试验。现将相关情况公告如下： 二、药品的其他情况 SHR-7787 注射液为 1 类治疗用生物制品，通过诱导激活 T 细胞，使其发挥 靶向杀伤肿瘤细胞的作用。目前国内尚无同类药物获批上市。截至目前，SHR-7787 注射液相关项目累计研发投入约为 4,893 万元。 药品名称 SHR-7787 注射液 SHR-4849 注射液 贝伐珠单抗 注射液 阿得贝利单抗 注射液 剂型 注射剂 申请事项 临床试验 受理号 CXSL ...

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-154 江苏恒瑞医药股份有限公司 关于获得药物临床试验批准通知书的公告 受 理 号：CXHL2500661、CXHL2500662、CXHL2500663、CXHL2500664 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 7 月 8 日受理的 HRS-2129 片符合药品注册的有关要求，同意开展成人糖尿病 性周围神经病理性疼痛、成人骨关节炎疼痛适应症的临床试验。 二、药物的其他情况 HRS-2129 片拟用于治疗急慢性疼痛。经查询，目前国内尚无同靶点药物获 批上市。截至目前，HRS-2129 片相关项目累计研发投入约为 11,240 万元。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）子公司山东盛迪医 药有限公司、上海恒瑞医药有限公司收到国家药品监督管理局（以下简称"国家 药监局"）核准签发关于 HRS-2129 片的《药物临床试验批准通知书》，将于近 期开展临床试验。现将 ...

恒瑞医药（600276）(600276.SH)发布公告，近日，公司子公司山东盛迪医药有限公司、上海恒瑞医药 有限公司收到国家药品监督管理局(简称"国家药监局")核准签发关于HRS-2129片的《药物临床试验批准 通知书》，将于近期开展临床试验。 HRS-2129片拟用于治疗急慢性疼痛。经查询，目前国内尚无同靶点药物获批上市。截至目前，HRS- 2129片相关项目累计研发投入约为11,240万元。 ...